Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Teucrium Corn Fund — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Teucrium Corn Fund trades at $17.55. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| BIO | CORN | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $339.75 | $19.12 |
52-Week Low | $241.71 | $16.46 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
CORN stock trades at $17.55 with a slight 0.4% daily gain, showing bullish technical momentum with strong moving average support. The company's financial ratios remain undisclosed in current data, limiting fundamental visibility. Recent partnership news with Hormel Foods for CORN NUTS brand licensing provides potential growth catalyst, while technical indicators suggest continued upward pressure with key resistance at $18.
Outlook remains cautiously optimistic given bullish technical signals and brand expansion opportunities, though limited financial transparency presents valuation challenges. Key risks include commodity price volatility and competitive pressures in the snack food sector. Investors should monitor upcoming earnings for fundamental clarity while technical momentum supports near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
